一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer.
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
解析肿瘤微环境与系统性免疫宏观环境之间的相互作用对于开发更有效的癌症诊断和治疗策略至关重要。在此,我们建立了肺癌类器官(LCOs)与配对外周血单个核细胞(PBMCs)的凝胶-液体界面(GLI)共培养模型,该模型增强了免疫细胞与肿瘤类器官之间的相互作用,从而优化了对体内系统性抗肿瘤免疫的模拟。通过构建肺癌患者队列,我们证明GLI模型在αPD1治疗下的反应能够精确反映相应患者的免疫治疗结局。此外,我们通过功能性多组学分析剖析了GLI模型内由PBMC来源T细胞介导的各种肿瘤免疫过程,并表征了具有效应记忆样表型的循环肿瘤反应性T细胞(GNLY + CD44 + CD9 +)作为免疫治疗疗效的潜在指标。我们的研究结果表明,GLI共培养模型可用于开发精准免疫治疗的诊断策略,以及理解其潜在机制。
Deciphering interactions between tumor micro- and systemic immune macroenvironments is essential for developing more effective cancer diagnosis and therapeutic strategies.
Here, we established a gel-liquid interface (GLI) co-culture model of lung cancer organoids (LCOs) and paired peripheral-blood mononuclear cells (PBMCs), featuring enhanced interactions between immune cells and tumor organoids for optimized simulation of in vivo systemic anti-tumor immunity. By constructing a cohort of lung cancer patients, we demonstrated that the responses of GLI models under αPD1 treatment reflected the immunotherapy outcomes of the corresponding patients precisely.
Furthermore, we dissected the various tumor immune processes mediated by PBMC-derived T cells within GLI models through functional multi-omics analyses, along with the characterization of circulating tumor-reactive T cells (GNLY + CD44 + CD9 + ) with effector memory-like phenotypes as a potential indicator of immunotherapy efficacy.
Our findings indicate that the GLI co-culture model can be used to develop diagnostic strategies for precision immunotherapies, as well as understanding the underlying mechanisms.
MEMBER ACCOUNT
登录成功会直接打开下一页。